A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. - Kipps, Thomas J.; Eradat, Herbert; Grosicki, Sebastian; Catalano, John; Cosolo, Walter; Dyagil, Iryna S.; Yalamanchili, Sreeni; Chai, Akiko; Sahasranaman, Srikumar; Punnoose, Elizabeth; Hurst, Deborah; Pylypenko, Halyna (Leukemia & Lymphoma, 2015)